H.C. Wainwright initiated coverage on Alpha Cognition with a new price target
$ACOG
H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2026 | $20.00 | Outperform | Raymond James |
| 5/29/2026 | $12.00 | Buy | Maxim Group |
| 4/17/2026 | $14.00 | Buy | Craig Hallum |
| 3/18/2025 | $20.00 | Buy | H.C. Wainwright |
4 - Alpha Cognition Inc. (0001655923) (Issuer)
4 - Alpha Cognition Inc. (0001655923) (Issuer)
4 - Alpha Cognition Inc. (0001655923) (Issuer)
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to your institutional representative at B. Riley. There will be no live webcast of
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. "On behalf of the entire Board of Directors, we are pleased that Dr. Wills will serve as Chairman at this important time for Alpha Cognition," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "He brings a wealth of experience, strategic insight, and a deep understanding of our busi
Alpha Cognition, Inc. (ACOG: NASDAQ) ("Alpha Cognition" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a multicenter, post-approval Phase 4 study designed to further evaluate the tolerability profile of ZUNVEYL in clinical practice, in patients with Alzheimer's disease. The study will collect safety and tolerability data and will also explore changes in Alzheimer's dise
SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
8-K - Alpha Cognition Inc. (0001655923) (Filer)
SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
4 - Alpha Cognition Inc. (0001655923) (Issuer)
4 - Alpha Cognition Inc. (0001655923) (Issuer)
4 - Alpha Cognition Inc. (0001655923) (Issuer)
Raymond James initiated coverage of Alpha Cognition with a rating of Outperform and set a new price target of $20.00
Maxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00
Craig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00
ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan
Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management
Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch Executed second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's patients Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability in 2027 Company to host conference call and webcast today, March 26, at 4:30 p.m. ET Alpha Cognition Inc. (ACOG: NASDA
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic